Is Cynata Therapeutics Limited (CYYNF) a Buy, Sell, or Hold?
OTC : CYYNF
Cynata Therapeutics Limited
$0.004 USD
$0 (0.0%)
- Volume
- 220
- Average Volume
- 199
- Market Capitalization
- $973.82K
- P/E Ratio
- -0.30
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.22
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.49
Company Overview
OTC
Kilian Kelly
Biotechnology
Healthcare
CYYNF
2
AU
USD
Liquidity Metrics
0.00
2.49
2.49
2.30
0.00
Sales & Valuation
$1.89M
-31.51
0.76
-0.33
-0.03
Profitability
-$0.0458
-$9.39M
9887.90%
11901.92%
-179.37%
-186.25%
P/E Metrics
-0.30
-0.01
-0.01
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-42.17
1/9
$1.67M
$4.51M
$1.12M
-$19.73M
Key Metrics (TTM)
$89697.0
-1.06
-0.01
2.49
-179.37%
-353.74%
-327.10%
-303.59%
-1425 days
Company Executives
| Name | Title |
|---|---|
| Jolanta Airey | Chief Medical Officer |
| Kilian Kelly | MD, Chief Executive Officer & Director |
| Mathias Kroll | Chief Business Officer |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Cynata Therapeutics Limited (OTC:CYYNF) Stock
Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD). Beyond this, its development pipeline features CYP-004, currently in Phase III clinical trials for osteoarthritis, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. The company is also actively investigating treatments for numerous other medical conditions, including asthma, myocardial infarction (heart attack), coronary artery disease, acute respirator ... y distress syndrome (ARDS), brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis (IPF), and opportunities in renal transplantation. Crucially, Cynata has forged a strategic partnership with Fujifilm, which provides essential clinical and commercial manufacturing and supply services for its Cymerus-based therapeutic MSC products. Originally incorporated in 2003 as Eco Quest Limited, the company rebranded as Cynata Therapeutics Limited in October 2013.
2026-06-21 22:12:08
Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
Frequently Asked Questions
-
What is the current Cynata Therapeutics Limited (CYYNF) stock price?
-
Cynata Therapeutics Limited(OTC:CYYNF) stock price is $0.004 in the last trading session. During the trading session, CYYNF stock reached the peak price of $0.2225 while $0.004 was the lowest point it dropped to. The percentage change in CYYNF stock occurred in the recent session was 0.0% while the dollar amount for the price change in CYYNF stock was $0.
-
CYYNF's industry and sector of operation?
-
The OTC listed CYYNF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYYNF?
-
Jolanta Airey | Chief Medical Officer
Kilian Kelly | MD, Chief Executive Officer & Director
Mathias Kroll | Chief Business Officer
Peter Gordon Webse FCIS FCPA FGIA | Company Secretary
| -
How many employees does CYYNF have?
-
Number of CYYNF employees currently stands at 2. CYYNF operates from 100 Cubitt Street, Cremorne, VIC 3121, AU.
-
Link for CYYNF official website?
-
Official Website of CYYNF is: https://www.cynata.com
-
How do I contact CYYNF?
-
CYYNF could be contacted at phone #61 3 7067 6940 and can also be accessed through its website. CYYNF operates from 100 Cubitt Street, Cremorne, VIC 3121, AU.
-
How many shares of CYYNF are traded daily?
-
The average number of CYYNF shares traded daily for last 3 months was 199.
-
What is the market cap of CYYNF currently?
-
The market value of CYYNF currently stands at $973.82K with its latest stock price at $0.004